Founders Capital Management (Texas)’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.32M Buy
25,101
+406
+2% +$87.3K 2.73% 15
2026
Q1
$5.37M Sell
24,695
-76
-0.3% -$16.9K 2.62% 16
2025
Q4
$5.66M Sell
24,771
-125
-0.5% -$28.5K 2.94% 14
2025
Q3
$5.76M Sell
24,896
-277
-1% -$56.4K 3.05% 12
2025
Q2
$4.67M Sell
25,173
-148
-0.6% -$27.5K 2.8% 14
2025
Q1
$5.31M Sell
25,321
-6,208
-20% -$1.21M 3.43% 13
2024
Q4
$5.6M Sell
31,529
-1,090
-3% -$200K 3.55% 10
2024
Q3
$6.44M Sell
32,619
-239
-0.7% -$44.6K 3.92% 9
2024
Q2
$5.64M Sell
32,858
-622
-2% -$103K 3.65% 9
2024
Q1
$6.1M Sell
33,480
-297
-0.9% -$51.2K 4.12% 6
2023
Q4
$5.23M Sell
33,777
-364
-1% -$53.1K 3.8% 7
2023
Q3
$5.09M Sell
34,141
-1,484
-4% -$218K 3.89% 7
2023
Q2
$4.8M Buy
35,625
+47
+0.1% +$6.89K 3.49% 8
2023
Q1
$5.67M Sell
35,578
-372
-1% -$56.9K 4.34% 6
2022
Q4
$5.81M Buy
35,950
+9
+0% +$1.38K 4.37% 6
2022
Q3
$4.82M Sell
35,941
-276
-0.8% -$39.6K 3.94% 7
2022
Q2
$5.55M Sell
36,217
-2,315
-6% -$354K 4.37% 4
2022
Q1
$5.22M Hold
38,532
3.34% 6
2021
Q4
$5.22M Sell
38,532
-279
-0.7% -$33K 3.34% 6
2021
Q3
$4.19M Sell
38,811
-3,017
-7% -$345K 2.87% 9
2021
Q2
$4.71M Sell
41,828
-280
-0.7% -$31.5K 3.07% 8
2021
Q1
$4.56M Sell
42,108
-2,090
-5% -$224K 3.24% 8
2020
Q4
$4.74M Buy
+44,198
New +$4.25M 3.35% 8
2020
Q1
$3.82M Sell
50,124
-5,879
-10% -$501K 3.96% 5
2019
Q4
$4.96M Buy
56,003
+8,960
+19% +$744K 3.75% 6
2019
Q3
$3.56M Buy
47,043
+2,910
+7% +$200K 2.85% 12
2019
Q2
$3.21M Sell
44,133
-47
-0.1% -$3.69K 2.83% 12
2019
Q1
$3.56M Buy
44,180
+215
+0.5% +$17.6K 3.34% 10
2018
Q4
$4.05M Sell
43,965
-220
-0.5% -$19.3K 4.33% 5
2018
Q3
$4.18M Sell
44,185
-70
-0.2% -$6.64K 3.45% 6
2018
Q2
$4.1M Sell
44,255
-739
-2% -$72.2K 3.6% 6
2018
Q1
$4.26M Sell
44,994
-1,000
-2% -$110K 3.59% 3
2017
Q4
$4.45M Sell
45,994
-690
-1% -$65K 3.69% 3
2017
Q3
$4.15M Buy
46,684
+330
+0.7% +$25.1K 3.44% 3
2017
Q2
$3.36M Buy
46,354
+1,275
+3% +$85.7K 2.98% 4
2017
Q1
$2.94M Buy
+45,079
New +$2.83M 2.64% 6

Other funds holding ABBV

Founders Capital Management (Texas)'s ABBV Position: Q2 2026 in Review

Founders Capital Management (Texas) increased its AbbVie (ABBV) stake by 1.6% in Q2 2026, buying an estimated $87.3K and bringing the position to 25,101 shares worth $6.32M. The position accounts for 2.73% of the portfolio, ranked #15.

Founders Capital Management (Texas) first reported a position in ABBV in Q1 2017 and has held it in 36 quarters since. The position peaked at $6.44M in Q3 2024. 1,476 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Founders Capital Management (Texas) held 25,101 shares of AbbVie worth $6.32M as of Q2 2026.
  • Founders Capital Management (Texas) bought 406 AbbVie shares in Q2 2026, an estimated $87.3K.
  • AbbVie made up 2.73% of Founders Capital Management (Texas)'s portfolio in Q2 2026, its #15 holding.
  • Founders Capital Management (Texas) first reported a position in AbbVie in Q1 2017 and has held it in 36 quarters since.
  • Founders Capital Management (Texas)'s AbbVie position peaked at $6.44M in Q3 2024.
  • 1,476 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Founders Capital Management (Texas)'s 13F filing for Q2 2026, filed 21 Jul 2026.